Company / Accounts Receivable
Cartesian Therapeutics, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.1M
FY2025
5-year range
$872.0K / $9.9M
FY2021-FY2025
Trend
+27.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable returned to growth in FY2025 after 3 years of decline, reaching $1M.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of -31.2%.
Declined from $6M to $1M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -44.7%
- 5-Year CAGR
- -31.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -31.2%, indicating a declining trend.
- In FY2025, accounts receivable increased 27.9% year-over-year.
- Peak accounts receivable was recorded in FY2021.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1M | +27.9% |
| FY2024 | $872.0K | -85.1% |
| FY2023 | $5.9M | -11.0% |
| FY2022 | $6.6M | -33.5% |
| FY2021 | $9.9M | +37.2% |
| FY2020 | $7.2M | +44.5% |
| FY2019 | $5.0M | +2225.6% |
| FY2016 | $215.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026